N-Formyl-glycin-(4-nitro-phenylester) | 16935-69-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Formyl-glycin-(4-nitro-phenylester)
• 英文别名: (4-Nitrophenyl) 2-formamidoacetate；(4-nitrophenyl) 2-formamidoacetate
• CAS: 16935-69-6
• 化学式: C₉H₈N₂O₅
• 分子量: 224.173
• InChiKey: MTRXDBYYOPQFFD-UHFFFAOYSA-N

物化性质

• 沸点：
  493.0±30.0 °C(Predicted)
• 密度：
  1.387±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-Formyl-glycin-(4-nitro-phenylester) 在 盐酸 作用下， 生成 4-硝基苯基甘氨酸
  参考文献：
  名称：

  Davydov,V.D.; Debabov,V.G., Journal of General Chemistry of the USSR, 1967, vol. 37, p. 945 - 950

  摘要：

  DOI：
• 作为产物：
  描述：

  对硝基苯酚 、 N-甲酰甘氨酸 在 N,N'-二环己基碳二亚胺 作用下， 生成 N-Formyl-glycin-(4-nitro-phenylester)
  参考文献：
  名称：

  嘌呤，嘧啶和咪唑。第二十五部分。嘌呤核苷酸从头开始的生物合成序列中中间体的一些化学反应和相互转化导致咪唑核苷酸

  摘要：

  5-氨基-1-环己咪唑-4-羧酸的受控弱酸处理逐步导致形成5-氨基-1-环己咪唑，N'-环己基-α-甲酰基氨基乙am，α-氨基-N'-环己基乙am（或在较高的pHα- ñ -formylamino- ñ '-cyclohexylacetamide），并且还以更高的pH值，α氨基ñ '-cyclohexylacetamide。通过用甲酸-乙酸酐和α-氨基-N进行甲酰化，可以很容易地逆转去甲酰基化反应在缓冲水溶液中，用甲酸亚氨基乙酯盐酸盐将'-环己基乙am迅速转化为5-氨基-1-环己咪唑。所有中间体的结构均通过甘氨酸或氨基乙腈的交替合成得到证实。已经观察到与相应的5-氨基-1-β- D-核呋喃糖基咪唑-4-羧酸5'-磷酸相似的反应顺序，并讨论了该结果在生物合成途径演变方面的可能意义。 。

  DOI：

  10.1039/j39660002270

文献信息

• Purines, pyrimidines, and imidazoles part 54. Interconversion of some intermediates in the de novo biosynthesis of purine nucleotides
  作者：Noel J. Cusack、Gordon Shaw、Fatma I. Logemann

  DOI：10.1039/p19800002316

  日期：——

  decarboxylated in situ to 5-amino-1-(2-pyridyl)imidazole. Reaction of 2-N-formylamino-N-(2-pyridyl)acetamide with ammonia and ammonium chloride gave 5-aminoimidazole and a similar reaction with the nucleotide 2-N-formylglycineamide ribotide similarly gave evidence for aminoimidazole formation. 4-Cyano-5-imidazolone, prepared by reaction of 2-cyano-N-formylacetamide with nitrous acid and reduction of the

  分别从乙基或苄基α-氨基-α-氰基乙酸酯和甲酰胺酸乙酯盐酸盐制得的乙基和5-氨基-1-（2-吡啶基）咪唑-4-羧酸苄基酯和甲酰胺基酸盐的盐酸盐继而转化为5-氨基将氨基-1-（2-吡啶基）-咪唑-4-羧酸原位脱羧为5-氨基-1-（2-吡啶基）咪唑。的2-反应Ñ -formylamino- ñ - （2-吡啶基）与氨和氯化铵乙酰胺，得到5-氨基咪唑并与核苷酸类似的反应2- Ñ -formylglycineamide核糖核苷酸类似地提供了证据为氨基咪唑的形成。2-氰基-N反应制得的4-氰基-5-咪唑啉酮-亚甲酰乙酰胺与亚硝酸和在100°C下用氨和亚硫酸铵还原生成的羟基亚氨基衍生物，得到5-氨基咪唑-4-甲酰胺。讨论了所涉及反应的含义。
• Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
  申请人：Controlled Chemicals Inc.

  公开号：US20040204434A1

  公开（公告）日：2004-10-14

  The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing, or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose or carboxymethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.

  将一种可生物利用的药物（如阿片类镇痛剂）转化为吸收差的酯类前药或其他前药衍生物，可以降低其滥用潜力并延长其作用时间，然后再进行制剂。与许多现有的缓释制剂不同，其中活性药物可以通过咀嚼、碾碎或破坏含有活性药物的片剂或胶囊珠释放，本发明的前药片剂或胶囊珠的机械加工既不会释放活性药物，也不会影响前药转化为药物的控制。此外，含有本发明的前药或其他药物的片剂和胶囊珠可以与足够量的增稠剂（如羟丙基甲基纤维素或羧甲基纤维素）配制，以阻止不适当的静脉和鼻腔给药，因为这些制剂不适用于这些给药途径。
• COMPOUNDS AND METHODS FOR LOWERING THE ABUSE POTENTIAL AND EXTENDING THE DURATION OF ACTION OF A DRUG
  申请人：Shafer A. Jules

  公开号：US20070203165A1

  公开（公告）日：2007-08-30

  The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing, or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose or carboxymethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.

  将一种可生物利用的药物，如阿片类镇痛剂，转化为吸收差的酯前药或其他前药衍生物，然后进行制剂，可以降低其滥用潜力并延长其作用时间。与许多现有的持续释放制剂不同，其中活性药物可以通过咀嚼、压碎或破坏含有活性药物的片剂或胶囊珠释放，本发明的前药片剂或胶囊珠不会释放活性药物，也不会破坏前药转化为药物的控制。此外，含有本发明的前药或其他药物的片剂和胶囊珠可以配制足量的增稠剂，如羟丙甲纤维素或羧甲基纤维素，以防止不适当的静脉和鼻腔给药，因为这些制剂并不适用于这些给药方式。
• Oxycodone conjugates with lower abuse potential and extended duration of action
  申请人：Controlled Chemicals, Inc.

  公开号：EP1782834A2

  公开（公告）日：2007-05-09

  The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an active pharmaceutical agent can be released by chewing, crushing or otherwise breaking tablets or capsule beads containing the active pharmaceutical agent, such mechanical processing of tablets or capsule beads containing a prodrug of this invention neither releases the active drug nor compromises the controlled conversion of prodrug to drug. Moreover, tablets and capsule beads containing prodrugs of this invention or other drugs can be formulated with a sufficient amount of a thickening agent such as hydroxypropylmethylcellulose to impede inappropriate intravenous and nasal administration of formulations that are not indicated for these modes of administration.

  通过在配制前将生物可利用药物（如阿片类镇痛剂）转化为吸收性较差的酯类原药衍生物，可降低其滥用可能性并延长其作用时间。与许多现有的活性药剂缓释制剂不同，含有本发明原药的片剂或胶囊珠通过咀嚼、碾碎或其他方式破碎，活性药剂就会释放出来，而对含有本发明原药的片剂或胶囊珠进行这种机械加工，既不会释放出活性药物，也不会影响原药向药物的可控转化。此外，含有本发明原药或其他药物的片剂和胶囊珠剂可以配制足量的增稠剂，如羟丙基甲基纤维素，以防止不适合静脉注射和鼻腔给药的制剂，因为这些制剂并不适用于这些给药方式。
• OXYCODONE CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED DURATION OF ACTION
  申请人：Controlled Chemicals, Inc.

  公开号：EP1603597B1

  公开（公告）日：2010-01-06